about
Main Immunogenic Region Structure Promotes Binding of Conformation-Dependent Myasthenia Gravis Autoantibodies, Nicotinic Acetylcholine Receptor Conformation Maturation, and Agonist SensitivityThe lipid droplet coat protein perilipin 5 also localizes to muscle mitochondriaSilencing rapsyn in vivo decreases acetylcholine receptors and augments sodium channels and secondary postsynaptic membrane foldingParadoxical increase in TAG and DAG content parallel the insulin sensitizing effect of unilateral DGAT1 overexpression in rat skeletal muscleHinge-deleted IgG4 blocker therapy for acetylcholine receptor myasthenia gravis in rhesus monkeys.Proteasome inhibition with bortezomib depletes plasma cells and specific autoantibody production in primary thymic cell cultures from early-onset myasthenia gravis patientsGene-environment interaction research and transgenic mouse models of Alzheimer's disease.Increased expression of rapsyn in muscles prevents acetylcholine receptor loss in experimental autoimmune myasthenia gravis.Treatment of myasthenia gravis by preventing acetylcholine receptor modulation.Neuropathy-induced spinal GAP-43 expression is not a main player in the onset of mechanical pain hypersensitivityGuidelines for pre-clinical assessment of the acetylcholine receptor--specific passive transfer myasthenia gravis model-Recommendations for methods and experimental designsStandardization of the experimental autoimmune myasthenia gravis (EAMG) model by immunization of rats with Torpedo californica acetylcholine receptors--Recommendations for methods and experimental designsOverexpression of rapsyn in rat muscle increases acetylcholine receptor levels in chronic experimental autoimmune myasthenia gravis.Goodpasture antigen-binding protein/ceramide transporter binds to human serum amyloid P-component and is present in brain amyloid plaques.Glycine receptor antibodies in PERM: a new channelopathyThe effect of plasma from muscle-specific tyrosine kinase myasthenia patients on regenerating endplates.B cell characterization and reactivity analysis in multiple sclerosis.MuSK IgG4 autoantibodies cause myasthenia gravis by inhibiting binding between MuSK and Lrp4.The ceramide transporter and the Goodpasture antigen binding protein: one protein--one function?The auto-antigen repertoire in myasthenia gravis.Antibody effector mechanisms in myasthenia gravis-pathogenesis at the neuromuscular junction.In vivo electroporation of the central nervous system: a non-viral approach for targeted gene delivery.Targeting plasma cells with proteasome inhibitors: possible roles in treating myasthenia gravis?Pathophysiology of myasthenia gravis with antibodies to the acetylcholine receptor, muscle-specific kinase and low-density lipoprotein receptor-related protein 4.Autoantibodies to neurotransmitter receptors and ion channels: from neuromuscular to neuropsychiatric disorders.Guidelines for pre-clinical animal and cellular models of MuSK-myasthenia gravis.A novel method for making human monoclonal antibodies.Clonal heterogeneity of thymic B cells from early-onset myasthenia gravis patients with antibodies against the acetylcholine receptor.Autoantigen induced clonal expansion in immortalized B cells from the peripheral blood of multiple sclerosis patients.Low Current-driven Micro-electroporation Allows Efficient In Vivo Delivery of Nonviral DNA into the Adult Mouse Brain.Erratum: gene-environment interaction research and transgenic mouse models of Alzheimer's disease.The expression of the Goodpasture antigen-binding protein (ceramide transporter) in adult rat brain.Characterization of an anti-fetal AChR monoclonal antibody isolated from a myasthenia gravis patient.A comprehensive analysis of the epidemiology and clinical characteristics of anti-LRP4 in myasthenia gravis.Immunoregulation in experimental autoimmune myasthenia gravis--about T cells, antibodies, and endplates.Effect of oxygen supply on passaging, stabilising and screening of recombinant Hansenula polymorpha production strains in test tube cultures.Effect of oxygen limitation and medium composition on Escherichia coli fermentation in shake-flask cultures.Proteomic analysis of rat tibialis anterior muscles at different stages of experimental autoimmune myasthenia gravis.Immunosuppression of experimental autoimmune myasthenia gravis by mycophenolate mofetil.Muscle-specific kinase myasthenia gravis IgG4 autoantibodies cause severe neuromuscular junction dysfunction in mice.
P50
Q27658065-AC25CB07-5572-4833-BBC6-A73DC765500AQ28568815-82C30A8F-6897-4E94-9DC4-879739EEF198Q28582435-61F09B65-56AA-478D-BC10-06E21CAC223EQ28743514-1BCA8C83-9A27-4929-9EA9-2E43BAE61DC0Q33681420-DCD1EE9B-D3AF-4716-A4A2-70096485EDDDQ34085747-FAA5A333-F525-45D4-BB19-67CB2A68BD2DQ34189447-DA4EFB96-5A20-4991-9FCD-43FBEB0C1342Q34560686-E4B00BF3-5101-4C5D-A3C1-2234C8F1910FQ34787808-A2DF8170-E504-49A9-BD40-94BC14D96D76Q35606194-E03CA882-8C99-4A45-B102-0FE0C3887F20Q35738827-0351CEF6-E164-4110-B282-8F579B939892Q35738911-70E01342-E0D7-4543-9ECC-9C319CA9E7B3Q35750195-A89FFA94-886F-403C-96DD-E4C7322CE903Q35922569-6A0A94C1-8CE5-4FEB-9DDE-47962A746E85Q36175200-2CD4F84A-2E85-4AB1-AFEB-702FEE04E520Q37362084-76AB68EB-AC91-4784-93D9-2AE163E00F3EQ37400354-1A3629CA-5BC0-4594-977B-EA675F64FB42Q37409458-9E75E72C-0A26-4B49-AF25-F0A31F41BA27Q37710735-3AF472A2-5662-4F09-9C22-34BDC35853CEQ37727984-6D93E73A-817E-47AD-810C-A339920C491FQ37727994-C7CA19B3-F882-4C3D-A383-5F933447D22FQ37799414-A82F7393-C2E2-41F1-9869-512113E06AAFQ38068534-71FEC5DA-2C04-454D-9E78-BADAFCA283CAQ38093711-EADEE933-0899-42BA-BC80-FFF4009B73A8Q38143031-40965ABE-2C16-424C-8227-BF3C03A18A9FQ38301487-A1F3DA62-8AF8-478B-BFAF-03711EAFAC06Q38341420-6DD796E5-5955-42EF-BC53-DD10259F585BQ39033342-E0A02575-35CE-4744-BA02-C59FB7A58D73Q39142634-B1D1A353-3009-4953-97BF-17A746E5A02FQ41279273-9C41CCC4-C782-4550-9C70-9940CD266442Q41807075-12F4DA57-9FBD-4EAF-B4A6-F6FC43A1DE9BQ42456040-87C26A37-6175-41A6-A56A-EC91966AC3A6Q43916530-98590B9F-BFFD-4589-BC23-37D0D5E5E027Q44608037-A8DBC67A-B1EF-450E-8492-FBA95D16D869Q44639080-4762742E-6BB4-4A46-A3D6-D28F6E6954DAQ44653152-9FEC729C-D6C0-4055-8AC1-682255C43483Q45008438-BCA4E423-DE87-4074-8F46-2E88EC81629CQ45198402-7237C424-FD32-4929-ADD4-A7289DEE2C4CQ46455000-63DF801C-B048-4FD3-A84F-B45C5A82E46BQ48626036-3574AA31-7EF3-49A0-AD5C-08E7E6F1966F
P50
description
hulumtues
@sq
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Mario Losen
@ast
Mario Losen
@en
Mario Losen
@es
Mario Losen
@nl
Mario Losen
@sl
type
label
Mario Losen
@ast
Mario Losen
@en
Mario Losen
@es
Mario Losen
@nl
Mario Losen
@sl
altLabel
M. Losen
@nl
prefLabel
Mario Losen
@ast
Mario Losen
@en
Mario Losen
@es
Mario Losen
@nl
Mario Losen
@sl
P106
P1153
6507635956
P21
P31
P496
0000-0002-9761-0002
P735
P7449
PRS1320386